Ashton M

Department of Pharmacology, University of Gothenburg, Sweden.

8 papers · 1 preprint

ArticleAyahuasca

Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects.

Äbelö A, Smallridge JW, von Rotz R +4

Europe PMC2025
ArticleAyahuasca

<i>N, N</i>-dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an <i>in vitro</i> investigation.

Eckernäs E, Macan-Schönleben A, Andresen-Bergström M +3

Europe PMC2023
ArticleDMT

Psychological and physiological effects of extended DMT.

Luan LX, Eckernäs E, Ashton M +10

Europe PMC2024
ArticleDMT

Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework.

Eckernäs E, Koomen J, Timmermann C +3

Europe PMC2023
PreprintDMT

Psychological and physiological effects of extended DMT

Luan LX, Eckernäs E, Ashton M +10

Europe PMC2023
ArticleDMT

N,N-dimethyltryptamine affects electroencephalography response in a concentration-dependent manner-A pharmacokinetic/pharmacodynamic analysis.

Eckernäs E, Timmermann C, Carhart-Harris R +2

Europe PMC2023
ArticleDMT

Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine - Implications for dose considerations.

Eckernäs E, Timmermann C, Carhart-Harris R +2

Europe PMC2022
ArticleDMT

Development and application of a highly sensitive LC-MS/MS method for simultaneous quantification of N,N-dimethyltryptamine and two of its metabolites in human plasma.

Eckernäs E, Bendrioua A, Cancellerini C +4

Europe PMC2022
ArticleDMT

Neural correlates of the DMT experience assessed with multivariate EEG.

Timmermann C, Roseman L, Schartner M +13

Europe PMC2019